Innovative therapeutics

Investors

Press Releases

 
Press Releases
  Date Title View
Apr 28, 2016
-First Quarter 2016 Total BioMarin Revenue Increases 16.7% Y/Y to $236.7 million -Vimizim Net Product Revenue Increases 43.5% Y/Y and Contributes $72.6 million in the First Quarter 2016; Vimizim Full-year Revenue Guidance Increased to $315 to $340 million - Kuvan Net Product Re...
Apr 21, 2016
SAN RAFAEL, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has enrolled the first patient in a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetyglucosaminidase (NAGLU) with a peptide der...
Apr 20, 2016
New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocityfor up to 12 months with Increases of 46%-65% from Baseline Phase 3 Randomized Controlled Study Planned to Start at End of 2016 SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharma...
Apr 20, 2016
Two High Dose Patients Show Increasing Levels of Factor VIII Above 50% Five of Six High Dose Patients Show Factor VIII Levels Above 5% SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today preliminary data from an ongoing Phase 1/2 clinical trial with BMN 270, an investigational g...
Apr 18, 2016
SAN RAFAEL, Calif., April 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will host an R&D Day from 8am (ET) to 12pm (ET) on Wednesday, April 20, 2016 in New York City. BioMarin management and external experts will provide an update to the investment community on the Company's development portfolio, which is focused on inn...
Apr 12, 2016
SAN RAFAEL, Calif., April 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 4:30 p.m. ET to discuss first quarter 2016 financial results and pr...
Mar 24, 2016
SAN RAFAEL, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that BMN 270, an investigational gene therapy for the treatment of hemophilia A, has been granted orphan drug designation by the European Commission. In the European Union, orphan drug designation is given to treatments that...
Mar 21, 2016
In 8-week Placebo-Controlled Portion No Benefit in Inattention or Mood Scores Were Observed Approximately, 60% of Patients Maintained Phe Levels At or Below Medical Guidelines over Long-Term Extension Study Conference Call and Webcast with Slides to Be Held Today at 8:30 AM ET...
Mar 3, 2016
-  Cowen and Company 36th Annual Health Care Conference on March 8 in Boston -  Raymond James 37th Annual Institutional Investors Conference on March 9 in Orlando -  Barclays Global Healthcare Conference on Ma...
Mar 2, 2016
80% Reduction in Clinical Disease Progression in One Year Compared to Natural History (p Company Plans to Submit Marketing Applications Starting Mid-Year 2016 SAN RAFAEL, Calif., March 02, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced positive...
Page:
1
... NextLast
= add release to Briefcase
img_bottom-content

Diseases

MPS I, MPS VI, PKU, LEMS, Lysosomal Storage Disorders, Morquio A/MPS IVA

Products

VIMIZIM™, Kuvan®, Naglazyme®, Aldurazyme®, Firdapse®

Patient/Physician Contact Information

BioMarin Patient and Physician Support (BPPS)
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: bpps@bmrn.com

Top